Skip to content

Advertisement

  • Poster presentation
  • Open Access

HLA-G-specific microRNAs a novel approach for targeting tumors

  • 1,
  • 2,
  • 2,
  • 3,
  • 3,
  • 1 and
  • 1
Journal for ImmunoTherapy of Cancer20131 (Suppl 1) :P174

https://doi.org/10.1186/2051-1426-1-S1-P174

  • Published:

Keywords

  • Renal Cell Carcinoma
  • Prognostic Marker
  • Surface Expression
  • Adaptive Immune Response
  • Protein Expression Level

Immune inhibitory molecules on immune cells as well as on tumor cells appear to play a key role in modulating the immunogenicity of tumors and the efficacy of immunotherapies. One mediator is represented by the non-classical HLA-G antigen, which is often overexpressed in human tumors when compared to corresponding normal tissues thereby inhibiting both innate as well as adaptive immune responses. Since discordant HLA-G transcript and protein expression levels were often found in tumors of distinct origin posttranscriptional control mechanisms have been recently suggested. Indeed, different HLA-G-specific miRs have been identified, which were able to downregulate HLA-G surface expression. The miR-mediated inhibition of HLA-G enhanced the NK cell recognition. These miRs were also differentially expressed in renal cell carcinoma (RCC) versus normal kidney epithelium. Immunohistochemical analysis demonstrated of a high frequency HLA-G expression in RCC lesions, which was associated with disease progression and inversely correlated with the expression of HLA-G-specific miRs. These data postulate that HLA-G-specific miRs might be used as prognostic markers as well as potential therapeutics for targeting HLA-G expressing RCC.

Authors’ Affiliations

(1)
Martin Luther University Halle-Wittenberg, Institute of Medical Immunology, Halle, Germany
(2)
University of Erlangen, Institute of Pathology, Erlangen, Germany
(3)
Martin Luther University Halle-Wittenberg, Institute of Molecular Medicine, Halle, Germany

Copyright

Advertisement